RHO

Gene

Related News

Opus Genetics Reports Progress in Gene Therapy Pipeline; Ultragenyx Announces Restructuring

Mar 10, 2026

Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.

Ocugen Completes Enrollment in Phase 3 Gene Therapy Trial for Retinitis Pigmentosa

Mar 03, 2026

Ocugen has completed enrollment of 140 patients in its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa. Topline data expected in Q1 2027 could support potential approval later that year.